1	Benzodiazepine Initiation Effect on Mortality Among Medicare Beneficiaries
2	Post Acute Ischemic Stroke
3	
4	Madhav Sankaranarayanan, MS ^a ; Maria A. Donahue, MD ^b ; Shuo Sun, PhD ^a ; Julianne D. Brooks, MPH ^a ;
5	Lee H. Schwamm, MD ^c ; Joseph P. Newhouse, PhD ^{d,e,f,g} ; John Hsu, MD, MBA, MSCE ^{d,h,i} ; Deborah
6 7	Blacker, MD, ScD ^{J,k} ; Sebastien Haneuse, PhD ^{a*} ; Lidia M.V.R. Moura, MD, PhD, MPH ^{b*}
8	^a Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
9	^b Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston,
10	Massachusetts.
11	^c Department of Neurology, Yale New Haven Health, School of Public Health, New Haven.
12	^d Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
13	^e Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston,
14	Massachusetts.
15	^f Harvard Kennedy School, Cambridge, Massachusetts.
16	^g National Bureau of Economic Research, Cambridge, Massachusetts.
17	^h Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts.
18	ⁱ Department of Medicine, Harvard Medical School, Boston, Massachusetts.
19	^j Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston,
20	Massachusetts.
21 22	^k Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
23	*These authors contributed equally.
24	
25	Short title:
26	Benzodiazepine Impact on Ischemic Stroke Survivors
27	
28	Corresponding author:
29	Madhav Sankaranarayanan
30	msankaranarayanan@bwh.harvard.edu
31	321 Franklin St. #2, Cambridge, MA 02139
32	
33	Total word count: 5,999

34 ABSTRACT

Rationale: Despite guideline warnings, older acute ischemic stroke (AIS) survivors still receive benzodiazepines (BZD) for agitation, insomnia, and anxiety despite being linked to severe adverse effects, such as excessive somnolence and respiratory depression. Due to polypharmacy, drug metabolism, comorbidities, and complications during the sub-acute post-stroke period, older adults are more susceptible to these adverse effects. We examined the impact of receiving BZDs within 30 days post-discharge on survival among older Medicare beneficiaries after an AIS.

41

42 Methods: Using the Medicare Provider Analysis and Review (MedPAR) dataset, Traditional fee-for-43 service Medicare (TM) claims, and Part D Prescription Drug Event data, we analyzed a random 20% 44 sample of TM beneficiaries aged 66 years or older who were hospitalized for AIS between July 1, 2016, 45 and December 31, 2019. Eligible beneficiaries were enrolled in Traditional Medicare Parts A, B, and D 46 for at least 12 months before admission. We excluded beneficiaries who were prescribed a BZD within 47 90 days before hospitalization, passed away during their hospital stay, left against medical advice, or 48 were discharged to institutional post-acute care. Our primary exposure was BZD initiation within 30 49 days post-discharge, and the primary outcome was 90-day mortality risk differences (RD) from 50 discharge. We followed a trial emulation process involving cloning, weighting, and censoring, plus we 51 used inverse-probability-of-censoring weighting to address confounding.

52

53 **Results:** In a sample of 47,421 beneficiaries, 826 (1.74%) initiated BZD within 30 days after discharge 54 from stroke admission or before readmission, whichever occurred first, and 6,392 (13.48%) died within 55 90 days. Our study sample had a median age of 79, with an inter-quartile range (IQR) of 12, 55.3% 56 female, 82.9% White, 10.1% Black, 1.7% Hispanic, 2.2% Asian, 0.4% American Native, 1.5% Other and 57 1.1% Unknown. After standardization based on age, sex, race/ethnicity, length of stay in inpatient, and 58 baseline dementia, the estimated 90-day mortality risk was 159 events per 1,000 (95% CI: 155, 166) for 59 the BZD initiation strategy and 133 events per 1,000 (95% CI: 132, 135) for the non-initiation strategy, 60 with an RD of 26 events per 1,000 (95% CI: 22, 33). Subgroup analyses showed RDs of 0 events per 61 1,000 (95% CI: -4, 11) for patients aged 66-70, 3 events per 1,000 (95% CI: -1, 13) for patients aged 71-62 75, 10 events per 1,000 (95% CI: 3, 23) for patients aged 76-80, 27 events per 1,000 (95% CI: 21, 46) for

- patients aged 81-85, and 84 events per 1,000 (95% CI: 73, 106) for patients aged 86 years or older. RDs
 were 34 events per 1,000 (95% CI: 26, 48) and 20 events per 1,000 (95% CI: 11, 33) for males and
 females, respectively. RDs were 87 events per 1,000 (95% CI: 63, 112) for patients with baseline
 dementia and 18 events per 1,000 (95% CI: 13, 21) for patients without baseline dementia.
- 68 **Conclusion:** Initiating BZDs within 30 days post-AIS discharge significantly increased the 90-day
- 69 mortality risk among Medicare beneficiaries aged 76 and older and for those with baseline dementia.
- 70 These findings underscore the heightened vulnerability of older adults, especially those with cognitive
- 71 impairment, to the adverse effects of BZDs.

- 72 INTRODUCTION
- 73

Every year in the United States, about 800,000 individuals have a stroke,¹ and three-quarters of all strokes occur in adults aged 65 and older, leading to around 610,000 hospital admissions annually.² Acute ischemic stroke (AIS) survivors are often given benzodiazepines (BZDs) during the immediate acute recovery period for periprocedural sedation or to manage insomnia, anxiety, and agitation, despite guideline warnings.^{3,4}

79

80 BZDs are associated with severe adverse effects, such as cognitive impairment, psychomotor 81 difficulties, excessive somnolence, pneumonia, respiratory depression requiring intubation, falls, and death.^{5–11} Older adults are especially susceptible due to age-related changes in drug metabolism, 82 polypharmacy, and comorbidities.¹² Patients who experience an AIS are particularly vulnerable to the 83 risks associated with BZD use,^{10,13} with pre-existing brain damage and gait comorbidities compounding 84 85 the established risks of falls and fall-related injuries. Alarmingly, various studies have shown that up to 86 15% of stroke patients receive BZDs, often indefinitely, and 50-80% of older patients using BZDs chronically experience adverse effects.^{3,6–9,14,15} 87

88

Despite state policies and national guidelines to curb BZD prescriptions, usage remains high.^{4,14} 89 90 There is a lack of data and studies on older adult outcomes among those receiving BZD prescriptions in 91 the sub-acute AIS recovery period. Trials among older adults are infeasible for several reasons: 92 exclusion criteria (e.g., comorbidities, polypharmacy, and functional limitations), recruitment barriers 93 (multimorbidity, disabilities, frailty, etc.), cognitive impairment, consent issues, drug interactions, adverse effects, and high drop-out rates, among others.¹⁶ We examined the impact of new outpatient 94 95 BZD prescriptions dispensed 30 days post-AIS discharge among Medicare beneficiaries 65 years or older. 96

- 97
- 98

99 **METHODS**

This study followed the Strengthening the Reporting of Observational Studies in Epidemiology
 (STROBE)¹⁷ reporting guidelines and was approved by the Mass General Brigham Institutional Review

102 Board. Because we conducted a secondary analysis of data collected for routine care and billing

103 purposes, the requirement for informed consent was waived. The data supporting this study's findings

104 are collected by The Centers for Medicare & Medicaid Services (CMS) and were made available by CMS

105 with no direct identifiers. All results were aggregated following CMS Cell Suppression Policies.

106 Restrictions apply to the availability of these data, which were used under license for this study.

Medicare data are available through CMS with their permission. The code that produced the findings is
 available upon reasonable request from any qualified investigator.

109

110 Eligibility Criteria

111 To properly define our target trial, we must establish the criteria for selecting patients in a 20% 112 random sample of Traditional Medicare Claims eligible for said trial. We identified 92,852 patients who 113 were admitted for AIS between July 1, 2016, and December 31, 2019, and enrolled in Traditional Fee-114 For-Service Medicare with at least one year of enrollment in Parts A (hospital insurance information), B 115 (preventative and medically necessary services or medical insurance information), and D (prescription 116 drug coverage information) before AIS hospitalization. We included patients admitted to an acute 117 hospital and discharged home (short-stay hospitalization). We included patients aged 66 and above in 118 the analysis. We excluded patients with a recorded AIS diagnosis 12 months before hospitalization and 119 patients with one or more recorded outpatient BZD prescriptions within three months before 120 admission. The final eligible sample consisted of 47,421 patients (Figure 1).

121

122 Study Design

123 The target trial would randomly assign eligible patients discharged alive after an AIS 124 hospitalization to one of two arms: i) BZD treatment upon discharge and ii) usual care with no BZDs for 125 30 days post-discharge. We modeled an emulated trial based on this target trial, which involved 126 random assignment of eligible patients upon discharge from AIS hospitalization to one of two arms: i) 127 treatment with BZD within the window extending from discharge to 30 days post-discharge (or 128 readmission date if within the 30 days); ii) no BZDs given within the defined window from discharge to 129 30 days post-discharge or readmission, whichever occurred first. We assessed the primary outcome of 130 mortality during a follow-up period spanning 90 days starting from discharge. Patients were followed

from discharge to the earliest of the following events: mortality, readmission, or end of study (i.e., 90 days post-discharge, including the discharge day). Further details regarding the observational analysis proposed for this emulated target trial can be found in Table 1.

134

135 Individual Characteristics

For each beneficiary, we captured demographic characteristics, i.e., age, documented sex,
reported race/ethnicity, dual Medicare and Medicaid eligibility status, and the original reason for
Medicare entitlement provided in Medicare's Master Beneficiary Summary (MBSF) File. We used the
self-reported race/ethnicity variable provided in MBSF (White, Black, Hispanic, Asian, American Native,
Other, Unknown).¹⁸

141

142 We used acute hospitalization records from the Medicare Provider Analysis and Review 143 (MedPAR) file and outpatient diagnosis codes in the Outpatient and Carrier Claims files. AIS hospitalizations were selected based on AIS ICD-10 code I63.¹⁹ We took the first hospitalization 144 145 chronologically for beneficiaries with more than one AIS hospitalization. We defined readmission as 146 any inpatient stay recorded post-stroke in the MedPAR file. We also obtained baseline stroke severity using the National Institutes of Health Stroke Scale (NIHSS) score.²⁰ We identified NIHSS scores in the 147 148 MedPAR files using ICD-10 codes R297.00 to R297.42, and we used the maximum NIHSS score in the 149 case of multiple scores. NIHSS scores range from 0 to 42, with higher values indicating a more severe stroke. We grouped NIHSS scores into two categories: Minor (\leq 4) and Moderate-to-High (>4).²¹ As an 150 151 additional measure of stroke severity at baseline, we used the length of stay (LOS) during AIS 152 admission. A shorter LOS has been associated with increased risks of early readmissions and postdischarge mortality.²² A U-shaped relationship between LOS and 30-day mortality has been described, 153 154 where both very short (1-2 days) and long (9-14 days) LOS were associated with high mortality rates 155 among patients with heart failure.²³

156

157 We captured comorbid conditions by leveraging all diagnoses present in the 12 months before 158 stroke admission. For each beneficiary, we evaluated the presence of a pre-admission history of 159 myocardial infarction (MI), congestive heart failure (CHF), peripheral vascular disease (PVD),

160 cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), paralysis, diabetes, renal
 161 disease, liver disease, rheumatism, and dementia²⁴ using ICD-10 diagnosis codes listed in Supplemental
 162 Table S1 and the National Cancer Institute's SEER-Medicare: Comorbidity SAS Macros.^{42,43} This
 163 algorithm requires that for outpatient claims, a patient's diagnoses (not just specific codes) must
 164 appear on at least two different claims more than 30 days apart. Additionally, we have death dates
 165 from the master beneficiary summary file (MBSF). We describe the characteristics of eligible patients
 166 stratified by BZD initiation strategy in Table 2.

167

168 Benzodiazepine Exposure and Treatment Assignment Procedures

In the target trial emulation, we obtained information on BZD prescriptions from outpatient
 pharmacy data. The BZD list can be found in Table S1 in the Supplement.

171

We addressed immortal time and confounding bias by deploying cloning techniques.^{25–27} Every 172 173 patient is "assigned" to both the control and treatment arm and "observed" until they deviate from 174 the protocol of the given arm. This effectively doubles our sample size, giving us perfectly balanced 175 arms concerning baseline characteristics. We accounted for this artificial doubling of the sample by "artificially" censoring the person-time for each patient clone when the actual treatment deviates from 176 177 the assigned treatment (e.g., a patient initiated on BZD within the 30-day exposure window would 178 have a clone in the control arm, contributing person-time until their initiation time). With this 179 approach, we aligned the discharge and assignment times directly. We accounted for the selection bias 180 due to this artificial censoring by using the inverse probability of censoring weighting (IPCW) on the 181 observations. We describe the cloning method in Figure S1 and "Technical Details" in the Supplement.

182

183 Statistical Analysis

To evaluate the effect of BZD initiation within the defined post-AIS exposure period on 90-day mortality, we estimated the survival probability of the patients using model-based predictions. After cloning and censoring the data, we weighted the expanded data using stabilized IPCWs to account for artificial censoring. The models for IPCW were pooled linear logistic regressions over person days, including age, sex, race/ethnicity, baseline dementia, and LOS as covariates, along with potential

interactions between them, separately for the two treatment strategies. For comparison, we estimated the unadjusted Kaplan-Meier and an unadjusted cubic spline model-based survival probabilities of mortality in the 90 days using the cloned dataset (see Figure S2 in the Supplement).

192

We fitted a pooled logistic regression model for mortality as a function of the following covariates: treatment strategy, a B-spline function with 5 degrees of freedom of time (measured in days post-discharge), and an interaction term between the treatment strategy and the B-spline for time to allow for time-varying effects using the expanded weighted data. We obtained estimated survival probabilities for each day under each treatment strategy and estimated the 90-day mortality risk difference.

199

200 We used the bootstrap method based on 500 re-samplings to obtain 95% Confidence Intervals 201 (CI), accounting for sample size inflation by cloning. See Technical Details in the Supplement for the 202 specifics of our statistical analysis.

203

204 Missing Data

We found no missing demographic information for the patients in our selected cohort. There was minimal missingness in the selected cohort's baseline medical conditions (4%). We assumed no baseline conditions for those without a recorded one. For NIHSS scores, there was a high missingness (58.6%). We performed a complete case analysis using NIHSS scores, sex, and dementia (please see the Supplement for these analyses).

210

211 **Pre-planned Stratified Analysis**

We repeated the analyses above, stratifying on age categories since BZDs are viewed as more detrimental to older patients. We also repeated our analyses stratified on baseline dementia, as BZD has more damaging effects in those with dementia.²⁸ Lastly, we stratified on sex since females are prescribed these medications more frequently and are more likely to experience side effects due to physiological and pharmacodynamic differences. We also conducted a secondary analysis stratifying on

NIHSS scores (<4 vs. >4) in patients with a reported NIHSS score, as BZDs may be more detrimental to
 patients with more severe AIS.

219

220 Secondary Analysis

In secondary analysis, we sought to include a marker of stroke severity at baseline because it has been associated with prescription probability and mortality risk. We examined the proportion of reported NIHSS scores, which was around 43% for the Medicare sample, and we relegated the use of NIHSS scores as a metric for stroke severity to the Supplement (Table S4, Figure S6-S11, and the Technical Details section).

- 226
- 227

228 **RESULTS**

229 Study Population Characteristics

In a sample of 235,912 beneficiaries discharged for an AIS during the study period, 47,421
patients met our inclusion criteria (Figure 1). Of these, 826 (1.74%) initiated BZDs within 30 days after
discharge from the stroke admission (or before readmission, whichever occurred first), and 6,392
(13.48%) passed away within 90 days. The median age of our study sample was 79 (IQR 12). Our
sample consisted of 55.3% female beneficiaries, 82.9% White, 10.1% Black/African American, 1.7%
Hispanic, 2.2% Asian, and 0.4% North American Native. We provide additional patient
demographic/clinical characteristics by BZD initiation strategy in Table 2.

238 **Outcome: Mortality**

After target trial emulation with cloning and adjustment for artificial censoring, the standardized 90-day risk of mortality was 159 events per 1000 (95% CI: 155,166) for those under the BZD initiation strategy and 133 events per 1000 (95% CI: 132,135) for those under the non-initiation strategy, which resulted in a risk difference of 26 events per 1000 patients (95% CI: 22,33). Figure 2 shows the standardized survival functions.

245 Looking at age categories, the 90-day risk differences were 0 events per 1000 (95% Cl: -4, 11) 246 for patients aged 66-70, 3 events per 1000 (95% CI: -1, 13) for patients aged 71-75, 10 events per 1000 247 (95% CI: 3, 23) for patients aged 76-80, 27 events per 1000 (95% CI: 21, 46) for patients aged 81-85, 248 and 84 events per 1000 (95% CI: 73, 106) for patients aged 86 years or older. Risk differences were 34 249 events per 1000 (95% CI: 26,48) and 20 events per 1000 (95% CI: 11,33) for male and female patients, 250 respectively. Risk differences were 87 events per 1000 (95% CI: 63,112) for patients with baseline 251 dementia and 18 events per 1000 (95% CI: 13,21) for patients without baseline dementia (Figure 3). 252 The standardized 90-day risks of mortality stratified by age categories, sex, and baseline dementia are 253 displayed in Table 3. The analysis in the subpopulation with reported NIHSS scores yielded results 254 similar to our primary analysis ("Additional Analysis" in the Supplement). The Supplementary Text 255 provides the Statistical Code used for the primary analysis.

- 256
- 257

258 **DISCUSSION**

259 Our results provide significant insights into the mortality risks associated with BZD initiation 260 following AIS among Medicare beneficiaries. There was an excess 90-day mortality risk for patients 261 who initiated BZDs within 30 days post-AIS discharge. This finding suggests that BZD use after an AIS 262 among patients over 76 years may be associated with increased mortality risk. When we further 263 analyzed by age groups, the mortality risk increased significantly with age; patients 86 years and older 264 had a higher risk than the 76-80 group.

265

Additionally, more female adults were initiated on BZDs than male adults. Perhaps the most striking finding was the significant excess mortality among patients with baseline dementia. Therefore, initiating BZDs should be based on carefully evaluating individual patient characteristics and weighing the potential benefits against the increased mortality risk.

270

271 While anxiety or insomnia can be managed with BZDs in the short term, the potential risks and 272 side effects are significant among older adults due to age-related changes in drug metabolism, 273 polypharmacy, and comorbidities.^{12,29} Of concern, BZDs can impair cognition (i.e., excessive

somnolence, drowsiness, dizziness, confusion, memory problems, and difficulties with attention, etc.),
cause or aggravate often related psychomotor issues (i.e., gait and balance issues), and can lead to hip
fracture, pneumonia, respiratory depression requiring intubation, and death.^{5–11,30,31} Lastly, the
sedating effects of BZDs on ambulation dexterity might have a more significant impact among AIS
survivors who can walk during the early days of recovery (e.g., those with mild AIS) and are at risk for
falls and fall-related injuries.^{6,10}

280

Despite state policies and national guidelines to curb BZD prescriptions, usage remains high,^{4,14} 281 especially among older adults who often receive 180 doses or more.³² The prevalence of BZD usage 282 283 among older adults in the United States increased from 1.1% to 17.6% between 2012 and 2013 (when 284 BZDs were added to the Medicare formulary), with a BZD use rate ranging from 8.6% to 20% among adults 65 years and older.³³ Of concern, many stroke patients receive BZD prescriptions indefinitely, 285 and the majority using BZDs chronically experience adverse effects.^{3,5–9,14,15} While BZD initiation 286 287 typically occurs at the hospital (where this type of medication might be of greater need), 4.7% of AIS 288 survivors received a new BZD prescription within the 90-day post-discharge window, and most were female patients.³⁴ We examined outcomes associated with initiating BZDs at discharge when there is a 289 290 great concern for this population, as prescriptions might be unnecessary, are not as closely supervised, 291 and frequency is not controlled. Long-term use of BZDs can lead to physical dependence, even at 292 therapeutic doses. For older stroke survivors, this poses additional risks because sudden 293 discontinuation can lead to withdrawal symptoms, including rebound anxiety, insomnia, depression, seizures, or delirium.^{11,35,36} 294

295

There is scarce data and studies on older adult patient outcomes among those receiving BZD prescriptions. When trials are infeasible, comparative effectiveness and safety studies leveraging realworld practice variation offer a powerful alternative.^{25,37,38} Additionally, we used techniques developed by Hernan et al. that allowed us to address two primary sources of bias arising from structuring initiation and using retrospective data using cloning.^{25–27} The first, known as immortal time bias, is due to a differing discharge time and BZD initiation time, leading to spurious interpretations of this lag. The second, known as confounding bias due to randomization, arises in retrospective settings as we did not

303 perform true randomization of our cohort. Using novel analytic strategies to emulate clinical trials that 304 would otherwise be infeasible or unethical, our study proves the utility of these techniques. It presents 305 meaningful results that should impact and reinforce BZD guidelines and improve health care for older 306 adults.

307

308 Our study provides valuable evidence suggesting that BZD initiation after AIS is associated with 309 increased mortality risk in Medicare beneficiaries, a greater risk observed predominantly among 310 individuals 76 years and older, males, and those with dementia. These findings underscore the 311 importance of careful consideration and individualized decision-making when managing post-stroke 312 care in older adults, weighing risks against potential benefits, and considering alternative treatments 313 when possible.

314

315 Limitations

The statistical analysis is contingent on modeling the survival function across the 90-day observation period. Due to the large sample size and long observation window, statistical results are sensitive to the initial specifications of the outcome model. In Technical Details (Supplement), we provide further details about our outcome model's exact specifications and justifications, which incorporate medical information and statistical parsimony.

321

The findings for our study population may not generalize to different age groups and patients with varying diagnoses or subtype etiology (i.e., intracerebral hemorrhage, infarction, cardiac embolism, etc.) and might not apply to Medicare Advantage beneficiaries. Due to data availability, our sample was limited to Traditional Medicare.

326

327 CONCLUSION

Initiating BZDs within 30 days post-AIS discharge significantly increased the 90-day mortality
 risk among Medicare beneficiaries aged 76 and older and those with baseline dementia.

330

- 332 FUNDING
- 333 NIH (1R01AG073410-01)
- 334

335 **DISCLOSURES**

- 336 M.A.D., J.D.B., M.P., L.H.S., S.H., and M.B.W. have no conflict of interest to disclose.
- 337 J.H. receives support from the National Institutes of Health, Agency for Healthcare Research and
- 338 Quality, Brandeis University, Altmed, Cambridge Health Alliance, Columbia University, Invitrx, and the
- 339 University of South Carolina and reports no conflict of interest.
- D.B. receives support from the National Institutes of Health and reports no conflict of interest.
- 341 J.P.N. is the National Committee for Quality Assurance director and reports no conflict of interest.
- L.M.V.R.M. receives support from NIH/NIA grants and the Epilepsy Foundation of America and reports
- 343 no conflict of interest.
- 344

345 SUPPLEMENTAL MATERIALS

- 346 Tables S1–S4
- 347 Figure S1-S12
- 348 Technical Details
- 349 Statistical Code

350 **REFERENCES**

- 1. CDC. Stroke Facts [Internet]. Stroke. 2024 [cited 2024 Jul 10];Available from:
- 352 https://www.cdc.gov/stroke/data-research/facts-stats/index.html
- Ovbiagele B, Goldstein LB, Higashida RT, Howard VJ, Johnston SC, Khavjou OA, Lackland DT,
 Lichtman JH, Mohl S, Sacco RL, et al. Forecasting the future of stroke in the United States: a policy
 statement from the American Heart Association and American Stroke Association. *Stroke*.
 2013;44:2361–2375.
- 357 3. Moura LMVR, Yan Z, Donahue MA, Smith LH, Schwamm LH, Hsu J, Newhouse JP, Haneuse S, Blacker
 358 D, Hernandez-Diaz S. No short-term mortality from benzodiazepine use post-acute ischemic
 359 stroke after accounting for bias. *J Clin Epidemiol*. 2023;154:136–145.
- 360
 4. By the 2023 American Geriatrics Society Beers Criteria[®] Update Expert Panel. American Geriatrics
 361
 362 Society 2023 updated AGS Beers Criteria[®] for potentially inappropriate medication use in older
 363
 364
 365
 365
 366
 366
 366
 367
 367
 368
 369
 369
 360
 360
 360
 360
 361
 361
 362
 362
 363
 364
 365
 366
 366
 367
 367
 368
 369
 369
 369
 360
 360
 360
 361
 362
 361
 362
 362
 362
 363
 364
 365
 364
 365
 366
 367
 367
 368
 368
 369
 369
 360
 360
 361
 361
 362
 362
 362
 362
 364
 365
 366
 367
 367
 368
 368
 369
 369
 369
 360
 360
 361
 361
 362
 362
 362
 362
 362
 363
 364
 364
 365
 366
 367
 368
 368
 369
 369
 369
 361
 361
 362
 362
 362
 364
 364
 365
 366
 366
 367
 368
 368
 368
 36
- 5. Lee JS. Necessary evil or systemic failure of care? Use of benzodiazepine and antipsychotic
 medications in older people seeking emergency department care. J Am Geriatr Soc. 2022;70:698–
 700.
- 366 6. Díaz-Gutiérrez MJ, Martínez-Cengotitabengoa M, Sáez de Adana E, Cano AI, Martínez 367 Cengotitabengoa MT, Besga A, Segarra R, González-Pinto A. Relationship between the use of
 368 benzodiazepines and falls in older adults: A systematic review. *Maturitas*. 2017;101:17–22.
- 7. Vozoris NT, Fischer HD, Wang X, Stephenson AL, Gershon AS, Gruneir A, Austin PC, Anderson GM,
 Bell CM, Gill SS, et al. Benzodiazepine drug use and adverse respiratory outcomes among older
 adults with COPD. *Eur Respir J*. 2014;44:332–340.
- 8. Markota M, Rummans TA, Bostwick JM, Lapid MI. Benzodiazepine Use in Older Adults: Dangers,
 Management, and Alternative Therapies. *Mayo Clin Proc.* 2016;91:1632–1639.
- Gupta A, Bhattacharya G, Balaram K, Tampi D, Tampi RR. Benzodiazepine use among older adults.
 Neurodegener Dis Manag. 2021;11:5–8.
- Sun S, Lomachinsky V, Smith LH, Newhouse JP, Westover MB, Blacker D, Schwamm L, Haneuse S,
 Moura LMVR. Benzodiazepine Initiation and the Risk of Falls or Fall-Related Injuries in Older
 Adults Following Acute Ischemic Stroke. *medRxiv*. 2024;2024.02.06.24302430.
- 379 11. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. *JAMA Psychiatry*.
 380 2015;72:136–142.
- Pesante-Pinto JL. Clinical Pharmacology and the Risks of Polypharmacy in the Geriatric Patient.
 Phys Med Rehabil Clin N Am. 2017;28:739–746.

- Lin S-M, Yang S-H, Liang C-C, Huang H-K, Loh C-H. Association between benzodiazepine use and
 risks of chronic-onset poststroke pneumonia: a population-based cohort study. *BMJ Open*.
 2019;9:e024180.
- Wang F, Ma Z, Liu M, Wu X. Potentially inappropriate medications at admission and discharge in
 older adults: A comparison of the Beers 2019 and 2015 criteria. *Int J Clin Pharmacol Ther*.
 2020;58:299–309.
- Agarwal SD, Landon BE. Patterns in Outpatient Benzodiazepine Prescribing in the United States.
 JAMA Netw Open. 2019;2:e187399.
- Buttgereit T, Palmowski A, Forsat N, Boers M, Witham MD, Rodondi N, Moutzouri E, Navidad AJQ,
 Van't Hof AWJ, van der Worp B, et al. Barriers and potential solutions in the recruitment and
 retention of older patients in clinical trials-lessons learned from six large multicentre randomized
 controlled trials. *Age Ageing*. 2021;50:1988–1996.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative.
 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:
 guidelines for reporting observational studies. *BMJ*. 2007;335:806–808.
- 398 18. Eicheldinger C, Bonito A. More accurate racial and ethnic codes for Medicare administrative data.
 399 *Health Care Financ Rev.* 2008;29:27–42.
- McCormick N, Bhole V, Lacaille D, Avina-Zubieta JA. Validity of Diagnostic Codes for Acute Stroke
 in Administrative Databases: A Systematic Review. *PLoS One*. 2015;10:e0135834.
- 402 20. Runde D. Calculated Decisions: NIH stroke scale/score (NIHSS). *Emerg Med Pract*. 2020;22:CD6–
 403 CD7.
- Schlegel D, Kolb SJ, Luciano JM, Tovar JM, Cucchiara BL, Liebeskind DS, Kasner SE. Utility of the
 NIH Stroke Scale as a predictor of hospital disposition. *Stroke*. 2003;34:134–137.
- 406 22. Han TS, Murray P, Robin J, Wilkinson P, Fluck D, Fry CH. Evaluation of the association of length of
 407 stay in hospital and outcomes. *Int J Qual Health Care*. 2021;34:mzab160.
- Sud M, Yu B, Wijeysundera HC, Austin PC, Ko DT, Braga J, Cram P, Spertus JA, Domanski M, Lee
 DS. Associations Between Short or Long Length of Stay and 30-Day Readmission and Mortality in
 Hospitalized Patients With Heart Failure. *JACC Heart Fail*. 2017;5:578–588.
- 411 24. Moura LMVR, Festa N, Price M, Volya M, Benson NM, Zafar S, Weiss M, Blacker D, Normand S-L,
 412 Newhouse JP, et al. Identifying Medicare beneficiaries with dementia. *J Am Geriatr Soc*.
 413 2021;69:2240–2251.
- 414 25. Hernán MA, Wang W, Leaf DE. Target Trial Emulation: A Framework for Causal Inference From
 415 Observational Data. *JAMA*. 2022;328:2446–2447.

- 416 26. Hernán MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not
 417 Available. *Am J Epidemiol*. 2016;183:758–764.
- 418 27. Hernán MA, Robins JM. Estimating causal effects from epidemiological data. *J Epidemiol* 419 *Community Health*. 2006;60:578–586.
- 420 28. Wu C-C, Liao M-H, Su C-H, Poly TN, Lin M-C. Benzodiazepine Use and the Risk of Dementia in the
 421 Elderly Population: An Umbrella Review of Meta-Analyses. *J Pers Med*. 2023;13:1485.
- 422 29. Hoel RW, Giddings Connolly RM, Takahashi PY. Polypharmacy Management in Older Patients.
 423 Mayo Clin Proc. 2021;96:242–256.
- 424 30. Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: A
 425 systematic review. *Drug Alcohol Depend*. 2019;200:95–114.
- 31. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Von Korff M, Jackson LA. Use of opioids or
 benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. J
 Am Geriatr Soc. 2011;59:1899–1907.
- Shorr RI, Bauwens SF, Landefeld CS. Failure to limit quantities of benzodiazepine hypnotic drugs
 for outpatients: placing the elderly at risk. *Am J Med*. 1990;89:725–732.
- 431 33. Maust DT, Kim HM, Wiechers IR, Ignacio RV, Bohnert ASB, Blow FC. Benzodiazepine Use among
 432 Medicare, Commercially Insured, and Veteran Older Adults, 2013-2017. J Am Geriatr Soc.
 433 2021;69:98–105.
- 434 34. Torres VL, Brooks JD, Donahue MA, Sun S, Hsu J, Price M, Blacker D, Schwamm L, Newhouse JP,
 435 Haneuse S, et al. Benzodiazepine Utilization in Ischemic Stroke Survivors: Analyzing Initial Excess
 436 Supply and Longitudinal Trends. *Stroke*. 2024; In press.
- 437 35. Juergens SM. Problems with benzodiazepines in elderly patients. *Mayo Clin Proc.* 1993;68:818–
 438 820.
- 439 36. Maust DT, Petzold K, Strominger J, Kim HM, Bohnert ASB. Benzodiazepine Discontinuation and
 440 Mortality Among Patients Receiving Long-Term Benzodiazepine Therapy. JAMA Netw Open.
 441 2023;6:e2348557.
- 442 37. Moura LMVR, Donahue MA, Yan Z, Smith LH, Hsu J, Newhouse JP, Schwamm LH, Haneuse S,
 443 Hernandez-Diaz S, Blacker D. Comparative Effectiveness and Safety of Seizure Prophylaxis Among
 444 Adults After Acute Ischemic Stroke. *Stroke*. 2023;54:527–536.
- 38. Moura LM, Westover MB, Kwasnik D, Cole AJ, Hsu J. Causal inference as an emerging statistical
 approach in neurology: an example for epilepsy in the elderly. *Clin Epidemiol*. 2017;9:9–18.
- 447

448 **TABLES**

49 Table 1. Description of a Target Trial and The Corresponding Observational Study

449 450

. •	
Target Trial	Emulated trial
Eligibility Criteria	
Discharge for cerebrovascular accident between	Same
07/01/2016 and 12/31/2019 from any hospital, and	
enrolled in Traditional Medicare Part A, B, D 12 months	
before stroke admission	
Age ≥ 66	Same
Confirmed AIS	Same
Admitted to a short-stay hospital	Same
No previous history of AIS in the last 12 months before	No recorded diagnosis of AIS in the last 12 months
admission	before admission
No use of BZDs in the last 3 months prior to admission	No recorded prescription of BZDs in the last 3 months
	before admission
Treatment Strategies	
Treatment arm: Initiate BZD upon discharge, follow	Treatment arm: Initiate BZD within a defined window
prescription strategy for 30 days	extending from AIS discharge to either the 30th day
	post-discharge or readmission date, whichever occurs
Control arm: Subject to usual care without BZDs for 30	first.
days post-discharge	Control arm: Refrain from initiating BZD within a
	defined window extending from AIS discharge to
	either the 30th day post- discharge or readmission
	date, whichever occurs first.
Assignment Procedures	
Randomized treatment assignment	Emulated randomization*
Outcomes	
Time to death within 90 days post-discharge	Same
Follow-up	
Starts at randomization (discharge)	Starts at discharge
Ends at date of all-cause re-admission, death, loss to	Ends at date of all-cause re-admission, death (as
follow-up or end of study (90 days post-discharge);	recorded in Medicare data ⁺), loss to follow-up (date
whichever occurs first	of enrollment discontinuation [‡]) or end of study (90
	days post-discharge); whichever occurs first
Causal Contrast	
Intention-to-treat effect	Observational analog of intention-to-treat effect§
Statistical Analysis	
Intention-to-treat effect analysis of time to mortality,	Intention-to-treat effect analysis of time to mortality,
accounting for censoring.	accounting for censoring and baseline confounding.
Legend: AIS, Acute Ischemic Stroke; BZD, Benzodiazepine (see Table S2). *Emulated randomization using cloning (see
technical details). +Medicare data mortality: Dates obtaine	ed from Master Beneficiary Summary File, reliable metrics
for mortality. ‡Date of enrollment discontinuation: Readm	issions are a loss to follow-up; we do not have insurance

454 claims information inpatient, dates obtained from the Medicare Provider Analysis and Review file. §Analysis can be 455 consistent with "intention-to-treat" (treatment assignment as a strategy). However, the effect can also be analogous

456 to the "per-protocol" (when treatment strategy is considered a "protocol" that must be followed over time [grace

457 period]).

		BZD i		
Characteristics	Overall Sample	No (n=46051)	Yes (n=1372)	SMD
Age (median (IQR))	79 (12)	79 (12)	79 (14)	0.038
Age Categories (%)				
66-70	7963 (16.8)	7818 (16.8)	145 (17.6)	0.072
71-75	9465 (20.0)	9296 (20.0)	169 (20.5)	
76-80	9570 (20.2)	9425 (20.2)	145 (17.6)	
81-85	8648 (18.2)	8498 (18.2)	150 (18.2)	
86+	11775 (24.8)	11558 (24.8)	217 (26.3)	
Sex (%)				
Male	21192 (44.7)	20876 (44.8)	316 (38.3)	0.133
Female	26229 (55.3)	25719 (55.2)	510 (61.7)	
Race/Ethnicity (%)				
White	39333 (82.9)	38611 (82.8)	722 (87.4)	0.180
Black	4795 (10.1)	4748 (10.3)	47 (5.7)	
Asian	1055 (2.2)	1036 (2.2)	19 (2.3)	
Hispanic	796 (1.7)	781 (1.7)	15 (1.8)	
American Native	201 (0.4)	>190 (0.4)	<11 (0.7)	
Other	703 (1.5)	>692 (1.5)	<11 (1.0)	
Unknown	538 (1.1)	>527 (1.1)	<11 (1.1)	
US Regions (%)				
Midwest	10544 (24.0)	10387 (24.1)	157 (20.5)	0.095
Northeast	10464 (23.8)	10281 (23.8)	183 (23.9)	
Southeast	11230 (25.6)	11013 (25.5)	217 (28.3)	
Southwest	5127 (11.7)	5037 (11.6)	90 (11.7)	
West	6556 (14.9)	6436 (15.0)	120 (5.6)	
Year of Discharge (%)				
2016	6802 (14.3)	6682 (14.3)	120 (14.5)	0.042
2017	13695 (28.9)	13442 (28.8)	253 (30.6)	
2018	13375 (28.2)	13151 (28.2)	224 (27.1)	
2019	13549 (28.6)	13320 (28.7)	229 (27.7)	
Baseline Dementia (%)				
No	43039 (90.4)	42336 (90.9)	703 (85.1)	0.178
Yes	4382 (9.6)	4259 (9.1)	123 (14.9)	
History of MI (%)				
No	45204 (95.3)	44408 (95.3)	796 (96.4)	0.053
Yes	2217 (4.7)	2187 (4.7)	30 (3.6)	
CHF (%)				
No	39875 (84.1)	39174 (84.1)	701 (84.9)	0.022
Yes	7546 (15.9)	7421 (15.9)	125 (15.1)	
PVD (%)				
No	39906 (84.2)	39200 (84.1)	706 (85.5)	0.037
Yes	7515 (15.8)	7395 (15.9)	120 (14.5)	
CVD (%)				
No	40866 (86.2)	40142 (86.2)	724 (87.7)	0.044
Yes	6555 (13.8)	6453 (13.8)	102 (12.3)	
COPD (%)				
No	39979 (84.3)	39292 (84.3)	687 (83.2)	0.031

Table 2. Characteristics of Patients Stratified by Benzodiazepine Initiation

Yes	7442 (15.7)	7303 (15.7)	139 (16.8)		
Hemiplegia/Paraplegia (%)					
No	46918 (98.9)	46100 (98.9)	818 (99.0)	0.009	
Yes	503 (1.1)	>492 (1.1)	<11 (1.0)		
Diabetes (%)					
No	33223 (70.1)	32650 (70.1)	573 (69.4)	0.015	
Yes	14198 (29.9)	13945 (29.9)	253 (30.6)		
Renal Disease (%)					
No	39433 (83.2)	38733 (83.1)	700 (84.7)	0.044	
Yes	7988 (16.8)	7862 (16.9)	126 (15.3)		
Liver Disease (%)					
No	47283 (99.7)	46460 (99.7)	823 (99.6)	0.013	
Yes	138 (0.3)	>127 (0.3)	<11 (0.4)		
Rheumatic Disease (%)					
No	45790 (96.6)	44987 (96.5)	803 (97.2)	0.038	
Yes	1632 (3.4)	1608 (3.5)	23 (2.8)		
NIHSS* (median (IQR))	4 (8)	4 (8)	4 (7)	0.008	
NIHSS Categories* (%)					
≤ 4	11199 (57.1)	11015 (57.1)	184 (57.3)	0.004	
> 4	8411 (42.9)	8274 (42.9)	137 (42.7)		
Length of Stay (median	3 (2)	3 (2)	3 (2)	0.010	
(IQR))					

459

460 Legend: Characteristics of patients stratified by BZD initiation within 30 days post-discharge versus non-BZD initiation461 within 30 days post-discharge.

462 *Demographics of NIHSS scores are taken for the subset of the sample that has reported NIHSS scores

463 Note that the number of initiators (1372) is more than those who initiate before readmission (mentioned in the464 Results section as 826).

465

466 IQR, Inter-Quartile Range; BZD, Benzodiazepine; CHF, Congestive Heart Failure; COPD, Chronic Obstructive Pulmonary

467 Disease; CVD, Cardiovascular Disease; MI, Myocardial Infraction; NIHSS, National Institutes of Health Stroke Scale;
 468 PVD, Peripheral Vascular Disease.

PVD, Peripheral Vasc

469 Table 3. Standardized 90-Day Risks of Mortality

Covariate/	Initiators		Non-initiators		Risk Difference	
Stratum	Estimate	95% CI	Estimate	95% CI	Estimate	95% CI
Overall	159	(155,166)	133	(132,135)	26	(22,33)
Age						
66 to 70 years	55	(50 <i>,</i> 66)	55	(53 <i>,</i> 58)	0	(-4,11)
71 to 75 years	69	(66,81)	66	(63,69)	3	(-1,13)
76 to 80 years	103	(96,115)	92	(90,95)	10	(3,23)
81 to 85 years	161	(156 <i>,</i> 182)	135	(131,139)	27	(21,46)
86+	356	(345 <i>,</i> 379)	272	(268,277)	84	(73 <i>,</i> 106)
Sex						
Male	143	(136 <i>,</i> 157)	110	(107,112)	34	(26 <i>,</i> 48)
Female	172	(165 <i>,</i> 173)	152	(150,154)	20	(8,26)
Baseline Dementia						
No Dementia	129	(124,136)	111	(110,113)	18	(13,23)
Dementia	434	(410,458)	346	(339,355)	87	(63,112)

470 471

472 473

Legend: Standardized 90-day risk of mortality (events per 1000 individuals). CI, confidence intervals.

474 **FIGURES**

475

482

489

476 Figure 1. Schematic Describing Eligibility Criteria

478 Legend: Describes the sampling process resulting in a sample of 47,421 patients. Medicare data files used:
479 MedPAR (Inpatient data), MBSF (Summary data); Diagnosed for Acute Ischemic Stroke based on ICD-10 codes
480 (I63 and I63.9); Part A: Hospital Insurance, Part B: Medical Insurance; Part D: Drug coverage. AIS, Acute Ischemic
481 Stroke; FFS, Fee-for-Service.

483 Figure 2. Standardized Survival Curve by Benzodiazepine Initiation Strategy

Legend: pooled logistic regression survival curves for all patients. Blue: Strategy for benzodiazepine initiation
 within 30 days post-discharge from AIS admission. Red: Strategy for no benzodiazepine initiation within 30 days
 post-discharge from AIS admission. Shaded areas: 95% CIs were constructed using Bootstrap with 500
 replications.

490 491 Figure 3. Standardized Survival Curves, Stratified Based on Age, Sex, and Dementia

- 492 Legend: pooled logistic regression survival curves for patients of the given strata. Blue: Strategy for
- 493 benzodiazepine initiation within 30 days post-discharge. Red: Strategy for no benzodiazepine initiation within 30
 494 days post-discharge. Shaded areas: 95% of CIs were constructed using Bootstrap with 500 replications.







